Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by
progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It …

Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease.
Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is …

Background: The presence of emphysema is relatively common in patients with fibrotic
interstitial lung disease. This has been designated combined pulmonary fibrosis and …

Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …

The appropriate selection of lung transplant recipients is an important determinant of
outcomes. This consensus document is an update of the recipient selection guidelines …

Rationale: There are no risk stratification tools for morbidity and mortality in bronchiectasis.
Identifying patients at risk of exacerbations, hospital admissions, and mortality is vital for …

Objective To determine the prognostic value of pulmonary function test (PFT) trends at 1 and
2 years in interstitial lung disease (ILD) associated with systemic sclerosis (SSc). Methods …

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an
overall poor prognosis. A simple-to-use staging system for IPF may improve prognostication …

Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …

Interstitial lung disease (ILD) is a common pulmonary manifestation of rheumatoid arthritis.
There is lack of clarity around predictors of mortality and disease behaviour over time in …